Entering text into the input field will update the search result below

Allena Pharma's mid-stage basket study of ALLN-177 in hyperoxaluria underway

Jul. 23, 2018 9:20 AM ETAllena Pharmaceuticals, Inc. (ALNAQ) StockBy: Douglas W. House, SA News Editor
  • The first subjects have been treated in an open-label Phase 2 basket study (Study 206) evaluating Allena Pharmaceuticals' (NASDAQ:ALNA) lead candidate ALLN-177 in adults and adolescents with primary hyperoxaluria or enteric hyperoxaluria with advanced kidney disease and elevated plasma oxalate.
  • The trial will enroll 15-20 patients who will receive ALLN-177 for 12 consecutive weeks. The key endpoints are the change from baseline in 24-hour urinary oxalate excretion and plasma oxalate levels.
  • According to ClinicalTrials.gov, the estimated primary completion date is June 2019.
  • ALLN-177 is an orally available enzyme, oxalate decarboxylase, designed to degrade oxalate in the GI tract.

Recommended For You

More Trending News

About ALNAQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ALNAQ--
Allena Pharmaceuticals, Inc.